{"brief_title": "AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer", "brief_summary": "The primary purpose of the study is to determine the time to progression of the combination of study drug (AG-013736) and docetaxel versus docetaxel alone in patients who have not received prior chemotherapy for metastatic breast cancer. The secondary purpose of the study is to determine the dose of study drug that can be given with docetaxel administered on an every 3 week schedule.", "condition": ["Breast Neoplasms"], "intervention_type": ["Drug", "Drug", "Drug", "Drug"], "intervention_name": ["Placebo", "Docetaxel", "AG-013736 (axitinib)", "Docetaxel"], "description": ["5 mg twice daily [bid] continuous dosing", "Standard of care drug administration", "5mg twice daily [bid] continuous dosing", "Standard of care drug administration"], "arm_group_label": ["Docetaxel + Placebo", "Docetaxel + Placebo", "Docetaxel + AG-013736", "Docetaxel + AG-013736"], "criteria": "Inclusion Criteria: - Female patients with histologically/cytologically proven metastatic breast carcinoma (stage IV, or recurrent with local or regional spread or distant metastatic disease) - Adequate bone marrow, liver, and renal function Exclusion Criteria: - Adjuvant chemotherapy given in the past 12 months - Uncontrolled brain metastases", "gender": "Female", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "metastatic breast cancer", "mesh_term": ["Breast Neoplasms", "Docetaxel", "Axitinib"], "id": "NCT00076024"}